MX2022006892A - Compuesto agonista del receptor sensor de calcio y aplicación del mismo. - Google Patents
Compuesto agonista del receptor sensor de calcio y aplicación del mismo.Info
- Publication number
- MX2022006892A MX2022006892A MX2022006892A MX2022006892A MX2022006892A MX 2022006892 A MX2022006892 A MX 2022006892A MX 2022006892 A MX2022006892 A MX 2022006892A MX 2022006892 A MX2022006892 A MX 2022006892A MX 2022006892 A MX2022006892 A MX 2022006892A
- Authority
- MX
- Mexico
- Prior art keywords
- calcium
- application
- sensing receptor
- agonist compound
- receptor agonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911250088 | 2019-12-09 | ||
| PCT/CN2020/134598 WO2021115272A1 (zh) | 2019-12-09 | 2020-12-08 | 钙敏感受体激动剂化合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006892A true MX2022006892A (es) | 2022-10-07 |
Family
ID=76328843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006892A MX2022006892A (es) | 2019-12-09 | 2020-12-08 | Compuesto agonista del receptor sensor de calcio y aplicación del mismo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230041996A1 (https=) |
| EP (1) | EP4091623A4 (https=) |
| JP (1) | JP7796013B2 (https=) |
| KR (1) | KR20220110789A (https=) |
| CN (2) | CN114222578B (https=) |
| AU (1) | AU2020399030B2 (https=) |
| BR (1) | BR112022011127A2 (https=) |
| CA (1) | CA3159744A1 (https=) |
| MX (1) | MX2022006892A (https=) |
| TW (1) | TW202122410A (https=) |
| WO (1) | WO2021115272A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022257940A1 (zh) * | 2021-06-08 | 2022-12-15 | 北京拓界生物医药科技有限公司 | 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用 |
| EP4353248A4 (en) * | 2021-06-08 | 2024-10-23 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | CALCIUM-SENSITIVE RECEPTOR AGONIST COMPOSITION AND APPLICATION THEREOF |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0407097A (pt) * | 2003-04-23 | 2006-01-24 | Japan Tobacco Inc | Antagonista do casr |
| US8999932B2 (en) * | 2009-07-29 | 2015-04-07 | Kai Pharmaceuticals, Inc. | Therapeutic agents for reducing parathyroid hormone levels |
| EP2643292A1 (en) * | 2010-11-26 | 2013-10-02 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| JP2014508103A (ja) * | 2010-11-26 | 2014-04-03 | レオ ファーマ アクティーゼルスカブ | カルシウム感知受容体活性化合物 |
| HRP20161566T1 (hr) * | 2011-06-08 | 2017-02-24 | Kai Pharmaceuticals, Inc. | Terapijski agensi za reguliranje serumskog fosfora |
| CN109985228A (zh) * | 2011-11-10 | 2019-07-09 | 凯伊药品公司 | 拟钙剂及其使用方法 |
-
2020
- 2020-12-08 WO PCT/CN2020/134598 patent/WO2021115272A1/zh not_active Ceased
- 2020-12-08 BR BR112022011127A patent/BR112022011127A2/pt unknown
- 2020-12-08 CN CN202080057062.XA patent/CN114222578B/zh active Active
- 2020-12-08 AU AU2020399030A patent/AU2020399030B2/en active Active
- 2020-12-08 CA CA3159744A patent/CA3159744A1/en active Pending
- 2020-12-08 CN CN202410744948.1A patent/CN118496313A/zh active Pending
- 2020-12-08 JP JP2022534636A patent/JP7796013B2/ja active Active
- 2020-12-08 EP EP20899484.8A patent/EP4091623A4/en active Pending
- 2020-12-08 US US17/783,233 patent/US20230041996A1/en active Pending
- 2020-12-08 MX MX2022006892A patent/MX2022006892A/es unknown
- 2020-12-08 TW TW109143251A patent/TW202122410A/zh unknown
- 2020-12-08 KR KR1020227022472A patent/KR20220110789A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114222578B (zh) | 2024-06-25 |
| KR20220110789A (ko) | 2022-08-09 |
| AU2020399030B2 (en) | 2026-04-09 |
| CN118496313A (zh) | 2024-08-16 |
| AU2020399030A1 (en) | 2022-06-23 |
| CN114222578A (zh) | 2022-03-22 |
| TW202122410A (zh) | 2021-06-16 |
| BR112022011127A2 (pt) | 2022-08-23 |
| JP2023504904A (ja) | 2023-02-07 |
| EP4091623A1 (en) | 2022-11-23 |
| WO2021115272A1 (zh) | 2021-06-17 |
| EP4091623A4 (en) | 2024-01-03 |
| JP7796013B2 (ja) | 2026-01-08 |
| CA3159744A1 (en) | 2021-06-17 |
| US20230041996A1 (en) | 2023-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006892A (es) | Compuesto agonista del receptor sensor de calcio y aplicación del mismo. | |
| MY206098A (en) | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid | |
| PH12018501099A1 (en) | Novel biphenyl compound or salt thereof | |
| ZA202202097B (en) | Amino pyrimidine ssao inhibitors | |
| CL2021003019S1 (es) | Porción de dispositivo para administración de dosis. (divisional solicitud 200003174) | |
| ZA202200519B (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
| MY208377A (en) | Compounds | |
| JOP20200059A1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
| MX2014001375A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| JOP20180113A1 (ar) | مركبات ,تركيبات وطرق | |
| AU2020288567A8 (en) | Pyrrolopyrimidine compound and use thereof | |
| CR20160243A (es) | Composición herbicida sinérgica para el control de malezas a partir de combinaciones de 2,4-d-colina, glifosato y glufosinato | |
| MX2022008487A (es) | Degradadores de smarca2-vhl. | |
| SA520411406B1 (ar) | مركبات مثبطة لمستقبل حمض ليسوفوسفاتيديك 1 | |
| PH12020550616A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| WO2015114395A9 (en) | Process for the preparation of vortioxetine salts | |
| NZ703347A (en) | Use of 2-methylene-19-nor-(20s)-1α,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism | |
| EP4000086A4 (en) | Ion implantation system with mixture of arc chamber materials | |
| PH12021550452A1 (en) | Methods of treating mycobacterial infections using tetracycline compounds | |
| MX395521B (es) | Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas | |
| CO2020006789A2 (es) | Procedimiento para la preparación de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-ácido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmacéutico | |
| CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
| MX2020010085A (es) | Formulaciones que contienen péptidos. | |
| PH12021551838A1 (en) | Insecticidal compositions resistant to active ingredient degradation and process for preparation thereof | |
| IL290927A (en) | The composition used to combat metabolic diseases and uses of the composition |